Cargando…

Clinical impact of tumor location on the colon cancer survival and recurrence: analyses of pooled data from three large phase III randomized clinical trials

The aim of the present study was to determine whether or not the overall survival (OS) and disease‐free survival (DFS) were affected by the tumor location in patients who underwent curative resection for colon cancer in a pooled analysis of three large phase III studies performed in Japan. In total,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aoyama, Toru, Kashiwabara, Kosuke, Oba, Koji, Honda, Michitaka, Sadahiro, Sotaro, Hamada, Chikuma, Maeda, Hiromichi, Mayanagi, Shuhei, Kanda, Mitsuro, Sakamoto, Junichi, Saji, Shigetoyo, Yoshikawa, Takaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5673952/ https://www.ncbi.nlm.nih.gov/pubmed/28948714 http://dx.doi.org/10.1002/cam4.1208

Ejemplares similares

Impact of postoperative complications on the colorectal cancer survival and recurrence: analyses of pooled individual patients’ data from three large phase III randomized trials
por: Aoyama, Toru, et al.
Publicado: (2017)

Hazard rate of tumor recurrence over time in patients with colon cancer: implications for postoperative surveillance from three Japanese Foundation for Multidisciplinary Treatment of Cancer (JFMC) clinical trials
por: Maeda, Hiromichi, et al.
Publicado: (2017)

Risk Factors for Peritoneal Recurrence in Stage II to III Colon Cancer
por: Mayanagi, Shuhei, et al.
Publicado: (2018)

Development and validation of a prognostic nomogram for colorectal cancer after radical resection based on individual patient data from three large-scale phase III trials
por: Honda, Michitaka, et al.
Publicado: (2017)

The clinical impacts of postoperative complications after colon cancer surgery for the clinical course of adjuvant treatment and survival
por: Aoyama, Toru, et al.
Publicado: (2023)

Randomized phase III trial comparing surgery alone to UFT + PSK for stage II rectal cancer (JFMC38 trial)
por: Okuno, Kiyotaka, et al.
Publicado: (2017)

Phase III randomised trial comparing 6 vs. 12-month of capecitabine as adjuvant chemotherapy for patients with stage III colon cancer: final results of the JFMC37-0801 study
por: Tomita, Naohiro, et al.
Publicado: (2019)

Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer
por: Suto, Takeshi, et al.
Publicado: (2017)

Safety analysis of two different regimens of uracil–tegafur plus leucovorin as adjuvant chemotherapy for high-risk stage II and III colon cancer in a phase III trial comparing 6 with 18 months of treatment: JFMC33-0502 trial
por: Tsuchiya, Takashi, et al.
Publicado: (2014)

The clinical impact of Hangeshashinto (TJ-14) in the treatment of chemotherapy-induced oral mucositis in gastric cancer and colorectal cancer: Analyses of pooled data from two phase II randomized clinical trials (HANGESHA-G and HANGESHA-C)
por: Nishikawa, Kazuhiro, et al.
Publicado: (2018)

Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer
por: Munemoto, Yoshinori, et al.
Publicado: (2015)

Is the measurement of drain amylase content useful for predicting pancreas-related complications after gastrectomy with systematic lymphadenectomy?
por: Nakanishi, Koki, et al.
Publicado: (2020)

Erratum to: Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101)
por: Matsusaka, Satoshi, et al.
Publicado: (2015)

Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101)
por: Matsusaka, Satoshi, et al.
Publicado: (2015)

Initial safety report on the tolerability of modified FOLFOX6 as adjuvant therapy in patients with curatively resected stage II or III colon cancer (JFMC41-1001-C2: JOIN trial)
por: Kotaka, Masahito, et al.
Publicado: (2015)

Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane‐ and trastuzumab‐naïve patients with HER2‐positive, previously treated, advanced, or recurrent gastric cancer (JFMC45‐1102)
por: Nishikawa, Kazuhiro, et al.
Publicado: (2016)

Randomized phase II study of daily and alternate-day administration of S-1 for advanced gastric cancer (JFMC43-1003)
por: Tanaka, Hiroaki, et al.
Publicado: (2017)

Surveillance of Esophageal Cancer in the Republic of Uzbekistan from 2000 to 2018
por: Yusupbekov, Abror, et al.
Publicado: (2020)

Clinical Implication of Inflammation-Based Prognostic Score in Pancreatic Cancer: Glasgow Prognostic Score Is the Most Reliable Parameter
por: Yamada, Suguru, et al.
Publicado: (2016)

Factors associated with compliance and non-compliance by physicians in a large-scale randomized clinical trial
por: Oba, Koji, et al.
Publicado: (2006)

Meta-analysis of randomized clinical trials in the era of individual patient data sharing
por: Kawahara, Takuya, et al.
Publicado: (2018)

Estradiol Stabilizes p53 Protein in Breast Cancer Cell Line, MCF–7
por: Okumura, Naoki, et al.
Publicado: (2002)

Overexpression of MDM2 in MCF‐7 Promotes Both Growth Advantage and p53 Accumulation in Response to Estradiol
por: Saji, Shigehira, et al.
Publicado: (1999)

An individual patient data meta-analysis of adjuvant therapy with uracil–tegafur (UFT) in patients with curatively resected rectal cancer
por: Sakamoto, J, et al.
Publicado: (2007)

Clinical utility of the platelet-lymphocyte ratio as a predictor of postoperative complications after radical gastrectomy for clinical T2-4 gastric cancer
por: Inaoka, Kenichi, et al.
Publicado: (2017)

Myocardin-related transcription factor A (MRTF-A) activity-dependent cell adhesion is correlated to focal adhesion kinase (FAK) activity
por: Kishi, Takayuki, et al.
Publicado: (2016)

Treatment using oxaliplatin and S-1 adjuvant chemotherapy for pathological stage III gastric cancer: a multicenter phase II study (TOSA trial) protocol
por: Namikawa, Tsutomu, et al.
Publicado: (2018)

Preoperative predictors of postoperative complications after gastric cancer resection
por: Kanda, Mitsuro
Publicado: (2019)

Correction to: Preoperative predictors of postoperative complications after gastric cancer resection
por: Kanda, Mitsuro
Publicado: (2020)

Phase II clinical study of modified FOLFOX7 (intermittent oxaliplatin administration) plus bevacizumab in patients with unresectable metastatic colorectal cancer—CRAFT study
por: Tezuka, Tohru, et al.
Publicado: (2013)

Unique solvability of a crack problem with Signorini-type and Tresca friction conditions in a linearized elastodynamic body
por: Kashiwabara, Takahito, et al.
Publicado: (2022)

Gene Selection using a High-Dimensional Regression Model with Microarrays in Cancer Prognostic Studies
por: Kaneko, Shuhei, et al.
Publicado: (2012)

Enhancing the Lasso Approach for Developing a Survival Prediction Model Based on Gene Expression Data
por: Kaneko, Shuhei, et al.
Publicado: (2015)

Pooled extracellular receptor-ligand interaction screening using CRISPR activation
por: Chong, Zheng-Shan, et al.
Publicado: (2018)

Daikenchuto accelerates the recovery from prolonged postoperative ileus after open abdominal surgery: a subgroup analysis of three randomized controlled trials
por: Kono, Toru, et al.
Publicado: (2019)

Clinical Implications of Lysyl Oxidase-Like Protein 2 Expression in Pancreatic Cancer
por: Tanaka, Nobutake, et al.
Publicado: (2018)

Efficacy of enteral nutrients containing β-hydroxy-β-methylbutyrate, glutamine, and arginine for the patients with anastomotic leakage after gastrectomy: study protocol of a multicenter phase II clinical trial
por: Kanda, Mitsuro, et al.
Publicado: (2018)

Author Correction: Pooled extracellular receptor-ligand interaction screening using CRISPR activation
por: Chong, Zheng-Shan, et al.
Publicado: (2022)

Mutant KRAS and GNAS DNA Concentrations in Secretin-Stimulated Pancreatic Fluid Collected from the Pancreatic Duct and the Duodenal Lumen
por: Sadakari, Yoshihiko, et al.
Publicado: (2014)

The significance of relative dose intensity in adjuvant chemotherapy of pancreatic ductal adenocarcinoma—including the analysis of clinicopathological factors influencing relative dose intensity
por: Yabusaki, Norimitsu, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_no1a4tj6nn82e15ffpn47adh50